The increasing prevalence of obesity worldwide and its associated pressure on healthcare systems, along with the reputation of GLP-1 drugs for inducing significant weight loss (approximately 1525+%, significantly higher than previous generations of obesity drugs), are driving GLP-1 drug expansion into new markets like China
The risk for the average user appears low, but it has not been ruled out entirely
During this process, free radicals are produces
Therefore, treatment with GLP-1RAs shows favorable effects on anti-inflammation through the suppression of these proinflammatory cytokine and inflammatory signal pathways, as well as augmenting cholesterol efflux in the endothelium
Push it too far and you get the nausea, vomiting, and constipation that make the first few weeks of GLP-1 therapy so challenging